BIOCATALYST COMPRISING PHOTOAUTOTROPHIC ORGANISMS PRODUCING RECOMBINANT ENZYME FOR DEGRADATION OF HARMFUL ALGAL BLOOM TOXINS

    公开(公告)号:US20190263871A1

    公开(公告)日:2019-08-29

    申请号:US16307783

    申请日:2017-07-20

    申请人: Jason DEXTER

    发明人: Jason DEXTER

    摘要: The invention comprises a photoautotrophic organism, generally having simpler nutritional requirements than heterotrophic organisms, utilized as a chassis for the heterologous expression and function of enzymes, or derivatives of said enzymes, that show activity toward the degradation/detoxification of toxins known to be associated with and specific to harmful algal blooms. As an example, a cyanobacterial strain (Synechocystis sp. PCC 6803) modified to express Sphingomonas sp. USTB-05 MlrA enzyme functionality, showing the capability of degrading microcystins (results shown here) and nodularins, is presented. Under modelled natural conditions, results indicate that heterologous enzymatic activity against microcystin-LR is more stable over time when utilizing a photoautotrophic chassis in comparison to use of a heterotrophic bacterial strain. In addition, both the viability and cell density of the photoautotrophic host is maintained for a significantly longer period of time, compared to a heterotrophic host.

    Pharmaceutical use of α antigen or α antigen gene
    9.
    发明授权
    Pharmaceutical use of α antigen or α antigen gene 有权
    药物使用α抗原或α抗原基因

    公开(公告)号:US07622297B2

    公开(公告)日:2009-11-24

    申请号:US11896977

    申请日:2007-09-07

    CPC分类号: A61K39/04 A61K2039/53

    摘要: The α antigen-encoding gene and the α antigen protein suppress the production of interleukin-4 etc., improve the Th2 type cytokine-dominant state, and furthermore inhibit various conditions of allergic diseases such as IgE production, histamine release and eosinophil infiltration, and therefore they are very effective for the prevention or treatment of atopic diseases such as atopic dermatitis, asthma, allergic rhinitis, and allergic conjunctivitis, and more broadly allergic diseases.

    摘要翻译: α抗原编码基因和α抗原蛋白抑制白细胞介素-4等的产生,改善Th2型细胞因子显性状态,进一步抑制IgE产生,组胺释放和嗜酸性粒细胞浸润等过敏性疾病的各种病症, 因此它们对预防或治疗特应性皮炎,哮喘,过敏性鼻炎和过敏性结膜炎等特应性疾病以及更广泛的过敏性疾病非常有效。